Welcome to our dedicated page for InfuSystem Holdings news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on InfuSystem Holdings stock.
InfuSystem Holdings, Inc. (NYSE American: INFU) is a growing healthcare service provider specializing in delivering infusion pumps and related products and services to patients across the United States and Canada. The company is headquartered in Rochester Hills, Michigan, and operates from five strategically located facilities to ensure comprehensive coverage. InfuSystem facilitates outpatient care through a two-platform model: Patient Services and Device Solutions.
Patient Services offers a last-mile solution for clinic-to-home healthcare. This segment includes Oncology, Pain Management, Wound Therapy, and Lymphedema services. It focuses on delivering complex durable medical equipment directly to patients, ensuring they receive continuous care at home or other non-hospital settings.
Device Solutions supports the Patient Services platform by providing direct payer rentals, pump and consumable sales, and biomedical services and repair. This segment's goal is to enhance service orientation and secure additional business from its direct payer clients.
InfuSystem's innovative approach and strategic partnerships have made it a leader in the healthcare service sector. Recently, the company announced a sales and marketing partnership with Dignitana AB, a leader in scalp cooling technology. This collaboration allows InfuSystem to offer the FDA-cleared DigniCap Scalp Cooling System to help minimize hair loss for cancer patients undergoing chemotherapy. This partnership highlights InfuSystem's commitment to enhancing patient care and expanding its product offerings.
InfuSystem boasts a robust financial position, underpinned by its diversified service offerings and strong market presence. The company continues to explore new opportunities to grow and enhance its service delivery, ensuring that it remains at the forefront of the healthcare industry.
InfuSystem Holdings (NYSE American: INFU) reported third-quarter 2021 net revenues of $26.6 million, a 6% increase year-over-year. The company anticipates $14-15 million in annual revenue from a new biomedical services contract, alongside growth in Pain Management services. Despite a net loss of $0.4 million and a 27% decline in Adjusted EBITDA, management is optimistic about future growth, reaffirming full-year revenue guidance of $107-110 million. Operating cash flow increased by 15% to $14.6 million.
InfuSystem Holdings, Inc. will release its Q3 2021 financial results on November 15, 2021, before market opens. A conference call is scheduled for the same day at 9:00 a.m. Eastern Time to discuss the results. Interested parties can participate by calling (833) 366-1127 or through a live webcast available on the company’s website. InfuSystem is a leading provider of health care services, focusing on integrated therapy services and durable medical equipment.
InfuSystem Holdings, Inc. (NYSE American: INFU) has entered into an exclusive three-year agreement with a major U.S. health care provider to offer its InfuBLOCK pain management therapy. This service includes electronic infusion pumps for post-surgical pain management, a 24/7 clinical hotline, and biomedical services. The agreement is expected to drive future revenue, leveraging InfuSystem’s expertise in outpatient care. The company emphasizes its non-narcotic pain management approach, aiming to enhance patient satisfaction while avoiding opioid-related risks.
InfuSystem Holdings (NYSE: INFU) announced its participation in Lake Street Capital Markets’ 5th Annual Best Ideas Growth (BIG5) Conference on September 14, 2021. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will engage in one-on-one and group meetings with investors during the event. This invitation-only virtual conference features executive presentations from around 100 public growth companies and connects them with top institutional investors nationwide. InfuSystem provides outpatient care through Integrated Therapy Services and Durable Medical Equipment Services.
InfuSystem Holdings, Inc. (INFU) reported a Q2 2021 net revenue of $24.8 million, down 4% from the prior year. However, ITS segment revenue increased 5% to $16.3 million. Gross profit decreased 6% to $15.1 million, with a gross margin of 60.6%. Net income was $0.8 million, or $0.04/share, compared to $4.1 million or $0.19/share in Q2 2020. The company announced a $20 million stock repurchase program and revised its 2021 guidance to lower end estimates of $107 million to $110 million in net revenues.
InfuSystem Holdings (NYSE American: INFU) will release its second quarter 2021 financial results on August 12, 2021, before the market opens. The company, a leading provider of outpatient care for durable medical equipment, will host an investor conference call on the same day at 9:00 a.m. Eastern Time. Interested parties can join the call by dialing (833) 366-1127 or listening via a live webcast available on the company’s investor website. A replay will be accessible for 90 days post-call.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced a new stock repurchase program to buy back up to $20 million of its common stock through June 30, 2024. This program replaces the prior authorization that expired on December 31, 2020, and is intended to enhance shareholder value. CEO Richard DiIorio expressed confidence in the company's operations and future growth prospects, emphasizing the program's role in strategic capital allocation.
InfuSystem announced a strategic agreement with Bio Compression Systems to integrate Lymphedema Therapy into its Integrated Therapy Service platform. This addition marks the fourth therapy service for InfuSystem, complementing its existing offerings in Oncology, Pain Management, and Wound Care. The company expects significant revenue contributions from this new therapy beginning in 2022. InfuSystem's recent CHAP accreditation will facilitate new patient onboarding within 60 days, addressing approximately 20% of the Lymphedema market.
InfuSystem Holdings, a prominent healthcare service provider, will participate in Craig-Hallum’s 18th Annual Institutional Investor Conference on June 2, 2021. CEO Rich DiIorio and CFO Barry Steele will engage in virtual one-on-one meetings throughout the day. Investors can contact Craig-Hallum or Lytham Partners for meeting arrangements. InfuSystem operates under two platforms: Integrated Therapy Services, focusing on complex durable medical equipment for outpatient care, and Durable Medical Equipment Services, which enhances service offerings to clients.
InfuSystem Holdings reported a strong performance for Q1 2021, with net revenues of $24.5 million, a 14% increase year-over-year. The company achieved a net income of $0.7 million, up $1.1 million from the prior year, alongside an Adjusted EBITDA of $6.2 million, marking a 51% growth. The Adjusted EBITDA margin was 25.2%. InfuSystem reaffirmed its 2021 full-year guidance, anticipating revenues between $107 million and $110 million, with a projected Adjusted EBITDA margin of 27%.
FAQ
What is the current stock price of InfuSystem Holdings (INFU)?
What is the market cap of InfuSystem Holdings (INFU)?
What services does InfuSystem Holdings, Inc. provide?
What are the two platforms of InfuSystem's services?
Where is InfuSystem Holdings, Inc. headquartered?
Who are InfuSystem's recent partners?
What is the DigniCap Scalp Cooling System?
What areas does InfuSystem serve?
What is the objective of the Patient Services platform?
How does the Device Solutions platform support InfuSystem?
What are InfuSystem's business segments?
How does InfuSystem contribute to patient care?
